메뉴 바로가기
주메뉴 바로가기
컨텐츠 바로가기
Quratis

We hope to become a company with a social impact that leads the human public health.

Press

[2019.06.25] A future K-Bio star.show off one's technical skills
관리자|2019-06-25 Hit|1,557

A future K-Bio star.show off one's technical skills


Future promising bio technologies will get together to showcase their technological prowess. It will unveil new drug pipelines to publicize the heightened level of R&D and attract corporate investment to speed up its listing in the future.

The Korea Bio Association and Mirae Asset Daewoo held a bio drug pipeline investment forum at Mirae Asset Daewoo's headquarters on Saturday. Introducing South Korea’s major bio drug development companies Pipeline, the company will establish a network between companies and institutional investment and secure opportunities for investment such as M&A by boosting participation in general companies.

"We will hold the forum as there is much interest in domestic and foreign investment in promising bio companies as well as in corporate partnership," said Kim Sung-jae, senior manager at Mirae Asset Daewoo. "This event will provide a great opportunity for companies to grow to the next level by providing a single look at key technological skills in the new drug development sector and sharing the current status of pipeline development."

The institute actively promoted vaccine treatments such as chronic hepatitis B vaccine, shingles vaccine and flu vaccine for the elderly. The hepatitis B treatment is an innovative new drug that activates the patient's immune system, and it has completed a clinical 1/2a award so far and is preparing a 2b award. The Chabaek Shin Institute will expand its use of vaccines such as infection, chronic diseases and anti-cancer vaccines by securing immune-reinforcement technology, a vaccine additive that increases vaccine antigen Depending on the clinical results, it will increase the possibility of success in overseas markets by considering export of technologies.

Quratis, which is developing a vaccine for tuberculosis, will then try to enter the KOSDAQ. The country's tuberculosis rate is the No. 1 among the OECD countries. Tuberculosis vaccines receive free vaccinations up to 59 months of age, but their effects will disappear in about 10 years. Preparations for teenagers and adults are needed. Curatis has conducted clinical one-phase trials on tuberculosis vaccines under development in the U.S. and South Africa, and is under way in South Korea with approval for a permission to test clinical 2a in 2017.